FDA fraud-busting pilot program aims at pharma

Earlier this week, HHS trumpeted its efforts to root out healthcare fraud and recover $4 billion for taxpayers, including about $2.5 billion attributed to violations of the False Claims Act, which has ensnared many drugmakers. But the agency has also started a little-known pilot program that it hopes will deliver still more returns. Report